Unitaid audited financial report for the year ended 31 December 2022
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Overview of mpox antivirals and diagnostics landscape
Next generation pulse oximeters technology and market landscape
Malaria diagnostics market and technology landscape
Landscape of innovative tools and delivery strategies for eliminating vertical transmission of HIV, syphilis, hepatitis B, and chagas in endemic areas
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Global malaria diagnostic and artemisinin treatment commodities demand forecast: 2017 – 2021 Report (May 2018)
Fever Diagnostic Technology Landscape
Multi-disease diagnostics landscape for integrated management of HIV, HCV, TB and other coinfections
Hepatitis C medicines technology and market landscape
Unitaid’s approach to intellectual property
Discussion Paper: Ensuring that essential medicines are also affordable medicines: challenges and options
Discussion Paper: An economic perspective on delinking the cost of R&D from the price of medicines
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
HIV/AIDS diagnostics technology landscape – 4th edition
Patents and licenses on antiretrovirals: a snapshot
HIV and congenital syphilis diagnostics technology landscape
The Trans-Pacific Partnership Agreement: [full report] Unitaid
The Trans-Pacific Partnership Agreement: implications for access to medicines and public health [executive summary], Unitaid
HIV/AIDS medicines technology and market landscape – 1st edition
Key Performance Indicators 2014
